PACB (Pacific Biosciences of California) Research & Development: $87.9 Mil (TTM As of Mar. 2026)


PACB Pacific Biosciences of California Inc PACB
53 GF Score
Price $1.60
GF Value $1.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Pacific Biosciences of California Research & Development?

Pacific Biosciences of California PACB +11.11% 53 Research & Development is $87.9 Mil as of Mar. 2026. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pacific Biosciences of California's Research & Development for the three months ended in Mar. 2026 was $19.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $87.9 Mil.

Pacific Biosciences of California  (NAS:PACB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pacific Biosciences of California Research & Development Related Terms

Pacific Biosciences of California Research & Development Historical Data

* Premium members only.

The historical data trend for Pacific Biosciences of California's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Biosciences of California Research & Development Chart

Pacific Biosciences of California Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.90 193.00 187.17 134.92 97.31

Pacific Biosciences of California Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.05 22.53 22.85 22.88 19.61
PACB
53GF Score
Pacific Biosciences of California Inc PACB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Biosciences of California Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $87.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $87.9 Mil mean?
Pacific Biosciences of California (PACB) has a Research & Development of $87.9 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Pacific Biosciences of California and its competitors.
Is Pacific Biosciences of California's Research & Development too high?
Pacific Biosciences of California's current Research & Development is $87.9 Mil. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Research & Development compare to CATX and LAB?
Pacific Biosciences of California's Research & Development of $87.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Research & Development is $87.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.60 — trading 1.2% below its estimated fair value. The current Research & Development is $87.9 Mil. Pacific Biosciences of California's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Research & Development is $87.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued. The current stock price of $1.60 is trading 1.2% below its estimated GF Value™ of $1.62. GuruFocus considers Pacific Biosciences of California to be Fairly Valued.

Key valuation signals for PACB:

  • Research & Development: $87.9 Mil
  • GF Value™: $1.62 vs. price of $1.60 (1.2% below fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Other Exchanges P09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score

Get the complete analysis for PACB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price
$1.62
GF Value